Click Refresh to update. Market summary here.
[stock_quote symbol=”SNPX” template=”%price% %change% %changep%”]
[table id=10 /]
NEW YORK, Feb. 7, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the BIO CEO & Investor Conference to be...
Read MoreNEW YORK, Jan. 25, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that Dr. Daniel Alkon, President and CSO, will provide a corporate overview at the NobleCon 14th Annual Institutional Investor Conference to be...
Read MoreNEW YORK, Jan. 5, 2018 /PRNewswire/ — Neurotrope (NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer’s disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin regimen who did...
Read MoreNew York – December 18, 2017 – Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced the appointment of Charles S. Ryan, JD, PhD as Chief Executive Officer and Director. The appointment follows...
Read MoreNEW YORK, Dec. 19, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that it will present additional clinical findings from its Phase 2 bryostatin trial in patients with advanced AD in a keynote...
Read MoreNEW YORK – August 9, 2017 – Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today provided a business update outlining recent clinical development progress and financial results for the quarter ended June...
Read MoreNEW YORK, July 19, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP) today presented clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer’s disease (AD) patients treated with 20 µg bryostatin-1 showed preliminary evidence of sustained improvement in cognition compared to placebo. The...
Read MoreThe presentation will be given by Dr. Martin R. Farlow, MD, Vice-Chairman for Research in the Department of Neurology, Indiana University School of Medicine, Indiana Alzheimer Disease Center. It will feature results from Neurotrope’s recently completed Phase 2 study of bryostatin – a protein kinase...
Read MoreData indicate that Bryostatin-1 improves cognition and the ability to perform activities of daily living Conference Call to Be Held Today, May 1, 2017, at 8:30 a.m. Eastern Time NEW YORK, May 1, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP) today announced positive top-line...
Read MoreBegins Trading on the NASDAQ Capital Market on March 29, 2017. Neurotrope Will Ring the Opening Bell on March 31, 2017 NEW YORK, March 27, 2017 PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s...
Read MoreDr. Alkon to Discuss Neurotrope’s Regenerative Approach to Alzheimer’s Disease and Other Neurological Diseases by Turning on the Brain’s Endogenous Ability to Increase Synapses NEW YORK, March 24, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative...
Read MoreNEW YORK, March 16, 2017 PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer’s disease, today announced that it is scheduled to present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017...
Read MoreTop-line efficacy data is expected to be announced in April 2017 NEW YORK, February 28, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced the conclusion of dosing and patient...
Read MoreNEW YORK, February 7, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), announces that Susanne Wilke PhD, Neurotrope’s Chief Executive Officer, and Dr. Daniel Alkon, Neurotrope’s President and...
Read MoreCreates potential for an economical and commercially viable supply of Bryostatin-1 NEW YORK, Jan 30, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that it has signed a licensing...
Read MoreNEW YORK, Jan 27, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital...
Read MoreNEW YORK, January 12, 2017, /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that its Board of Directors has approved a 1-for-32 reverse stock split of the Company’s issued...
Read MoreNEW YORK, January 5, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that Dr. Susanne Wilke, Ph.D., Neurotrope’s Chief Executive Officer, will be presenting a corporate overview at two investor...
Read MoreNEW YORK, November 23, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today issued a statement on Eli Lilly’s experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical...
Read MoreTop line Phase 2 study results expected to be released in April 2017 The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million NEW YORK, November 22, 2016 /PRNewswire/ —...
Read MoreFunding to complete Phase 2 trial in Alzheimer’s with top line results expected April 2017 Initiate clinical trial for Fragile X indication which has Orphan Drug Status File Application with the Nasdaq Capital Market New York, NY. November 18, 2016 Neurotrope, Inc. (OTCQB:NTRP),...
Read MoreNew York, NY, September 28, 2016 — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today announced that it has appointed its Chief Scientific Officer, Dr. Daniel Alkon, to the additional role of President. After approximately...
Read MoreNEWARK, N.J., September 6, 2016 — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today announced that it has appointed Dr. Susanne Wilke, PhD as Chief Executive Officer. Dr. Wilke brings significant leadership, sector and investing...
Read MoreNEW YORK, N.Y., August 15, 2016 (GLOBE NEWSWIRE) — Neurotrope, Inc. (OTCBB:NTRP) today announced that its wholly owned subsidiary, Neurotrope BioScience, Inc., has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1...
Read MoreReaches Agreement with Iroquois Master Fund NEWARK, N.J., August 5, 2016 — Neurotrope, Inc. (OTCBB:NTRP) (the “Company”), focused on developing drugs to treat neurological diseases including Alzheimer’s disease, today announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain...
Read MoreTherapeutics that target PKC Epsilon to Restore Lost Brain wiring show unique potential to treat both Genetic Mental Retardation (Fragile X) and Alzheimer’s Disease NEWARK, N.J., June 13, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP): Dr. Daniel Alkon, Chief Scientific Officer of Neurotrope, discussed “Modulation...
Read MoreNEWARK, N.J., May 18, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), is pleased to announce that it has entered into a research collaboration with the International Rett Syndrome Foundation,...
Read MoreBryostatin, currently being tested in a Phase 2b clinical trial in Alzheimer’s Dementia, causes regeneration of synaptic networks in both Alzheimer’s and Fragile X mouse models, neurodegenerative diseases at both ends of the age spectrum, providing a potential major step toward a universal regenerative...
Read MoreInterim Data Anticipated Q1 2017 Newark, NJ, February 11, 2016 – Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s...
Read MoreInterim Data Anticipated Q1 2017 Newark, NJ, February 11, 2016 – Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease. ...
Read MoreMore than 150 Attendees from 30 Sites Nationwide Newark, NJ, February 3, 2016 – Neurotrope, Inc. (NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the treatment of...
Read MoreExisting Preferred Stock Investors Convert to Common Stock, Substantially Increasing Shareholders’ Equity. Exercise of Strategically Designed Warrant Package Could Result in Over $100 million in Additional Funding Newark, NJ, November 16, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that it has entered into definitive...
Read MoreNewark, NJ, July 20, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) will be showcasing bryostatin as a potential treatment for Alzheimer’s Disease at the Alzheimer’s Association International Conference(R)(AAIC) being held July 18-23, 2015, in Washington,...
Read MorePre-clinical study funded by SOAR-NPC to examine effects of bryostatin in NPC mice. Newark, NJ, June 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary (“Neurotrope”), will conduct a preclinical study, in collaboration with a leading...
Read MoreStudies to evaluate the effects of bryostatin-1 in a Fragile X Syndrome mouse model over a thirteen week period Newark, NJ, April 16, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant...
Read MoreNewark, NJ, April 6, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the...
Read MoreStudy Meets Primary Endpoint of Safety and Tolerability Newark, NJ, February 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced positive top-line results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer’s disease...
Read MoreStudy Meets Primary Endpoint of Safety and Tolerability Newark, NJ, February 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced positive top-line results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer’s disease (AD)....
Read MoreNewark, NJ, January 13, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer’s Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD,...
Read MoreNewark, NJ, January 6, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 – 14, 2015. Charles S. Ramat,...
Read MoreNeurotrope’s Collaborator BRNI, Publishes Article in the Journal of Alzheimer’s Disease describing correlation of PKCe levels and degree of disease Plantation, FL – August 18, 2014 – Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, “PKCe Deficits in...
Read MorePlantation, FL – July 29, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer’s disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C...
Read More– Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 – Plantation, FL – July 22, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the...
Read MorePlantation, FL – July 18, 2014 – Neurotrope, Inc. (OTCQB: NTRP) today announced that on July 16, 2014, its Board of Directors appointed Co-Chairmen Charles S. Ramat and Paul Freiman as Co-Chief Executive Officers on an interim basis, effective immediately. Messrs. Ramat and Freiman replace...
Read More– Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 – Plantation, FL. – July 15, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the...
Read More– Neurotrope creates Office of the Chairman with Messrs. Ramat and Freiman as Co-Chairman of the Board. Dr. John Abeles to Remain on Board – Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and...
Read More– Dr. Kongsamut specializes in age-related and neuroscience/CNS disorders – Plantation, FL. – June 4, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today the appointment of Sam Kongsamut, Ph.D., as Executive Director, Pharmacology, effective immediately. In this role, Dr. Kongsamut will be responsible...
Read More– Preclinical data demonstrates reduction of Alzheimer’s brain deficits to lower toxic Aβ and restored synaptic loss – Plantation, FL. – May 28, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today the publication of positive human cell culture and mouse model data of Bryostatin...
Read MorePlantation, FL. – May 20, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has signed an agreement with Stanford University to study and, along with Dr. Paul Wender, investigate certain analogs of bryostatin, referred to as “bryologs”, as potential...
Read MorePlantation, FL. – April , 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has applied for a provisional patent with the U.S. Patent & Trademark Office to protect its ability to use and commercialize its Bryostatin technology for the treatment of...
Read MorePlantation, FL. – December 16, 2013 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that James Gottlieb has been appointed to the Company’s Board of Directors. Mr. Gottlieb has extensive senior level experience in a broad range of positions in Washington, D.C., in the...
Read MorePlantation, FL. – January 28, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President,...
Read MorePlantation, FL. – January 14, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that Dr. James New, the Company’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ Tenth Annual Equity Conference 11:00AM Eastern Time on Tuesday, January...
Read MorePlantation, FL. – January 6, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that the Company will present at the Biotech Showcase 2014 conference 8:00AM Pacific Time on Monday, January 13, 2014 at the Parc 55 Wyndham Hotel, Union Square in San...
Read MorePlantation, FL. – October 22, 2013 – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that Paul E. Freiman has been appointed to the Company’s Board of Directors. Mr. Freiman has extensive pharmaceutical and biotechnology industry operating experience as a board member and Chief Executive Officer...
Read MorePlantation, FL. – October 15, 2013 – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that Dr. Larry D. Altstiel, M.D., Ph.D. has been appointed to the Company’s Scientific Advisory Board. Dr. Altstiel is an expert in several neurodegenerative disease states with respect to their potential...
Read MorePlantation, FL. – October 9, 2013 – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that it completed a closing of the sale of 1,080,000 shares of its Series A convertible preferred stock in a private offering to accredited investors, at a price of $1.00 per...
Read MorePlantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer. Mr. Weinstein had been the acting Chief...
Read MoreNeurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering Plantation, Fla. – August 29, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB: BLFLD), a Nevada corporation (the “Company”), announced today that it completed a reverse merger on August 23,...
Read More[table id=12 /]
[table id=11 /]
[table id=5 /]
Our Board sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of our Board to serve as a prudent fiduciary for stockholders and to oversee the management of our business. To fulfill its responsibilities and to discharge its duty, our Board follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as our Board deems appropriate in our best interest or as required by applicable laws and regulations.
[table id=2 /]
[table id=1 field=”filing_date” format=”date”/]